Arvinas Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arvinas wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arvinas is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Arvinas.

Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Sunday, February, 28th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.21. The company had revenue of $2.22 million for the quarter, compared to analysts' expectations of $7.46 million. Arvinas had a negative trailing twelve-month return on equity of 46.99% and a negative net margin of 403.77%.
View Arvinas' earnings history.

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARVN stock has increased by 44.1% and is now trading at $63.49.
View which stocks have been most impacted by COVID-19.

9 brokers have issued twelve-month target prices for Arvinas' shares. Their forecasts range from $45.00 to $140.00. On average, they anticipate Arvinas' stock price to reach $106.45 in the next year. This suggests a possible upside of 67.7% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Some companies that are related to Arvinas include Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Zai Lab (ZLAB), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR) and TG Therapeutics (TGTX).
View all of ARVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $63.49.

Arvinas has a market capitalization of $3.10 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

Arvinas employs 133 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected]